The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases

Mauro Maccarrone, Natalia Battista, Diego Centonze

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Endocannabinoids are endogenous agonists of cannabinoid receptors, and comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine) and 2-arachidonoylglycerol are the best-studied members of this class of lipid mediators, and it is now widely accepted that their in vivo concentration and biological activity are largely dependent on a "metabolic control." Therefore, the proteins that synthesize, transport and degrade endocannabinoids, and that together with the target receptors form the so-called "endocannabinoid system," are the focus of intense research. This new system will be presented in this review, in order to put in a better perspective the impact of its modulation on Huntington's disease. In particular, the effect of agonists/antagonists of endocannabinoid receptors, or of inhibitors of endocannabinoid metabolism, will be discussed in the context of onset and progression of Huntington's disease, and will be compared with other neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, and amyotropic lateral sclerosis. Also the plastic changes of endocannabinoids in multiple sclerosis will be reviewed, as a paradigm of their impact in neuroinflammatory disorders.

Original languageEnglish
Pages (from-to)349-379
Number of pages31
JournalProgress in Neurobiology
Volume81
Issue number5-6
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Endocannabinoids
Huntington Disease
Neurodegenerative Diseases
Cannabinoid Receptor Agonists
Motor Neuron Disease
Ethers
Protein Transport
Unsaturated Fatty Acids
Amides
Multiple Sclerosis
Parkinson Disease
Alzheimer Disease
Esters
Lipids
Research

Keywords

  • Alzheimer's disease
  • Amyotropic lateral sclerosis
  • Endocannabinoids
  • Huntington's disease
  • Multiple sclerosis
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The endocannabinoid pathway in Huntington's disease : A comparison with other neurodegenerative diseases. / Maccarrone, Mauro; Battista, Natalia; Centonze, Diego.

In: Progress in Neurobiology, Vol. 81, No. 5-6, 04.2007, p. 349-379.

Research output: Contribution to journalArticle

@article{fa8e77a9aeea418f89bfadd1512b16cf,
title = "The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases",
abstract = "Endocannabinoids are endogenous agonists of cannabinoid receptors, and comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine) and 2-arachidonoylglycerol are the best-studied members of this class of lipid mediators, and it is now widely accepted that their in vivo concentration and biological activity are largely dependent on a {"}metabolic control.{"} Therefore, the proteins that synthesize, transport and degrade endocannabinoids, and that together with the target receptors form the so-called {"}endocannabinoid system,{"} are the focus of intense research. This new system will be presented in this review, in order to put in a better perspective the impact of its modulation on Huntington's disease. In particular, the effect of agonists/antagonists of endocannabinoid receptors, or of inhibitors of endocannabinoid metabolism, will be discussed in the context of onset and progression of Huntington's disease, and will be compared with other neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, and amyotropic lateral sclerosis. Also the plastic changes of endocannabinoids in multiple sclerosis will be reviewed, as a paradigm of their impact in neuroinflammatory disorders.",
keywords = "Alzheimer's disease, Amyotropic lateral sclerosis, Endocannabinoids, Huntington's disease, Multiple sclerosis, Parkinson's disease",
author = "Mauro Maccarrone and Natalia Battista and Diego Centonze",
year = "2007",
month = "4",
doi = "10.1016/j.pneurobio.2006.11.006",
language = "English",
volume = "81",
pages = "349--379",
journal = "Progress in Neurobiology",
issn = "0301-0082",
publisher = "Elsevier Limited",
number = "5-6",

}

TY - JOUR

T1 - The endocannabinoid pathway in Huntington's disease

T2 - A comparison with other neurodegenerative diseases

AU - Maccarrone, Mauro

AU - Battista, Natalia

AU - Centonze, Diego

PY - 2007/4

Y1 - 2007/4

N2 - Endocannabinoids are endogenous agonists of cannabinoid receptors, and comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine) and 2-arachidonoylglycerol are the best-studied members of this class of lipid mediators, and it is now widely accepted that their in vivo concentration and biological activity are largely dependent on a "metabolic control." Therefore, the proteins that synthesize, transport and degrade endocannabinoids, and that together with the target receptors form the so-called "endocannabinoid system," are the focus of intense research. This new system will be presented in this review, in order to put in a better perspective the impact of its modulation on Huntington's disease. In particular, the effect of agonists/antagonists of endocannabinoid receptors, or of inhibitors of endocannabinoid metabolism, will be discussed in the context of onset and progression of Huntington's disease, and will be compared with other neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, and amyotropic lateral sclerosis. Also the plastic changes of endocannabinoids in multiple sclerosis will be reviewed, as a paradigm of their impact in neuroinflammatory disorders.

AB - Endocannabinoids are endogenous agonists of cannabinoid receptors, and comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine) and 2-arachidonoylglycerol are the best-studied members of this class of lipid mediators, and it is now widely accepted that their in vivo concentration and biological activity are largely dependent on a "metabolic control." Therefore, the proteins that synthesize, transport and degrade endocannabinoids, and that together with the target receptors form the so-called "endocannabinoid system," are the focus of intense research. This new system will be presented in this review, in order to put in a better perspective the impact of its modulation on Huntington's disease. In particular, the effect of agonists/antagonists of endocannabinoid receptors, or of inhibitors of endocannabinoid metabolism, will be discussed in the context of onset and progression of Huntington's disease, and will be compared with other neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, and amyotropic lateral sclerosis. Also the plastic changes of endocannabinoids in multiple sclerosis will be reviewed, as a paradigm of their impact in neuroinflammatory disorders.

KW - Alzheimer's disease

KW - Amyotropic lateral sclerosis

KW - Endocannabinoids

KW - Huntington's disease

KW - Multiple sclerosis

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=34047139505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047139505&partnerID=8YFLogxK

U2 - 10.1016/j.pneurobio.2006.11.006

DO - 10.1016/j.pneurobio.2006.11.006

M3 - Article

C2 - 17276576

AN - SCOPUS:34047139505

VL - 81

SP - 349

EP - 379

JO - Progress in Neurobiology

JF - Progress in Neurobiology

SN - 0301-0082

IS - 5-6

ER -